The 83% objective response rate bexobrutideg posted in Phase 1 is almost indistinguishable from the 81.6% pirtobrutinib achieved in the BRUIN trial — which makes the design of Nurix’s new Phase 3 study the most consequential decision in the program. Rather than picking a soft comparator, Nurix and Roche have pointed the DAYBreak CLL-306 trial directly at pirtobrutinib, the drug that received traditional FDA approval in December 2025 for post-covalent BTK inhibitor CLL. That is a high-stakes wager: win the head-to-head and bexobrutideg owns the sequencing narrative in relapsed/refractory CLL; fail to beat it and the entire rationale for BTK degradation over non-covalent inhibition is publicly tested and found wanting.
The trial’s structure sharpens that risk further. CLL-306 will randomize roughly 620 patients 1:1, with dual primary endpoints of objective response rate and progression-free survival assessed by an independent review committee. Running two co-primary endpoints simultaneously means the statistical plan must deliver on both to support the superiority label the submission will need. The 600 mg once-daily oral dose of bexobrutideg is unchanged from Phase 1, which at least removes formulation uncertainty, and a parallel tablet-formulation study in healthy volunteers is running quietly in the background to open immunology and neurology pathways later. The broader Nurix-Roche collaboration is also layering in a combination cohort with venetoclax, with or without an anti-CD20 antibody, through a separate Phase 1/2 study — so CLL-306 is not the only iron in the fire, but it is the one that defines what degradation is worth commercially.
What distinguishes bexobrutideg mechanistically is the degrader approach itself. A BTK degrader eliminates the protein rather than occupying its active site, which in theory addresses resistance mutations that blunt covalent and non-covalent inhibition alike. Phase 1 data presented at ASH 2024 showed a median PFS of 22.1 months and a median duration of response of 20.1 months in a heavily pretreated population — durable enough to justify the Phase 3 bet, but still short of the evidence needed to displace an already-approved standard. The brain-penetrant property adds a dimension pirtobrutinib also claims, so CNS activity alone will not differentiate the label.
The single number to watch as enrollment ramps is the interim PFS readout. With progression-free survival as a co-primary, any protocol-specified interim analysis will be the first public test of whether degradation duration actually exceeds non-covalent inhibition in a randomized setting, and that data point will reset valuations, partnership terms, and the entire field’s confidence in the degrader-versus-inhibitor hypothesis.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
